» Articles » PMID: 27806080

Predicting the Mortality Benefit of CT Screening for Second Lung Cancer in a High-Risk Population

Overview
Journal PLoS One
Date 2016 Nov 3
PMID 27806080
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Patients who survive an index lung cancer (ILC) after surgical resection continue to be at significant risk for a metachronous lung cancer (MLC). Indeed, this risk is much higher than the risk of developing an ILC in heavy smokers. There is currently little evidence upon which to base guidelines for screening at-risk patients for MLC, and the risk-reward tradeoffs for screening this patient population are unknown. The goal of this investigation was to estimate the maximum mortality benefit of CT screening for MLC. We developed a computational model to estimate the maximum rates of CT detection of MLC and surgical resection to be expected in a given population as a function of time after resection of an ILC. Applying the model to a hypothetical high-risk population suggests that screening for MLC within 5 years after resection of an ILC may identify only a very small number of treatable cancers. The risk of death from a potentially resectable MLC increases dramatically past this point, however, suggesting that screening after 5 years is imperative. The model also predicts a substantial detection gap for MLC that demonstrates the benefit to be gained as more sensitive screening methods are developed.

Citing Articles

Prediction of lung cancer risk based on age and smoking history.

Bates J, Hamlington K, Garrison G, Kinsey C Comput Methods Programs Biomed. 2022; 216:106660.

PMID: 35114461 PMC: 8920760. DOI: 10.1016/j.cmpb.2022.106660.

References
1.
McMahon P, Hazelton W, Kimmel M, Clarke L . Chapter 13: CISNET lung models: comparison of model assumptions and model structures. Risk Anal. 2012; 32 Suppl 1:S166-78. PMC: 3478678. DOI: 10.1111/j.1539-6924.2011.01714.x. View

2.
Alberg A, Nonemaker J . Who is at high risk for lung cancer? Population-level and individual-level perspectives. Semin Respir Crit Care Med. 2008; 29(3):223-32. PMC: 3399915. DOI: 10.1055/s-2008-1076742. View

3.
Battafarano R, Force S, Meyers B, Bell J, Guthrie T, Cooper J . Benefits of resection for metachronous lung cancer. J Thorac Cardiovasc Surg. 2004; 127(3):836-42. DOI: 10.1016/j.jtcvs.2003.08.055. View

4.
Aberle D, DeMello S, Berg C, Black W, Brewer B, Church T . Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013; 369(10):920-31. PMC: 4307922. DOI: 10.1056/NEJMoa1208962. View

5.
FRIBERG S, Mattson S . On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997; 65(4):284-97. DOI: 10.1002/(sici)1096-9098(199708)65:4<284::aid-jso11>3.0.co;2-2. View